[Effects of cysteinyl leukotrienes receptor antagonists on chronic brain injury after global cerebral ischemia/reperfusion]. 2018

Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
Department of Neurology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China.

: To investigate the effects of cysteinyl leukotrienes receptor (CysLTR) antagonists on global cerebral ischemia/reperfusion (CI/R) injury in gerbils, and to explore its mechanism. : Totally 40 gerbils weighting 45-65 g were randomized into sham, saline, Pranlukast and HAMI 3379 groups with 10 animals in each. The CI/R model was established in gerbils by bilateral common carotid occlusion for 10 min followed by reperfusion. After ischemia, the CysLTR antagonists Pranlukast (0.1 mg/kg) and HAMI 3379 (0.1 mg/kg) were injected intraperitoneally for 5 consecutive days in the last two groups,while the former two groups were injected with saline only (10 mL/kg). After 24 h or 14 d reperfusion, neurological deficit score was evaluated and the behavioral dysfunction was assessed, respectively. And 14 d after reperfusion, the neuron morphology of cerebral cortex was observed in brain sections stained with Cresyl violet. In addition, the Iba-1 (microgila) and GFAP (astrocyte) positive cells in cerebral cortex were observed by using immunohistochemitry method. : CI/R models were successfully established in 21 out of 30 gerbils with 7 in saline group, 6 in Pranlukast group, and 8 in HAMI 3379 group. Compared with saline group, Pranlukast and HAMI 3379 significantly attenuated neurological deficits, improved the behavioral function 24 h after reperfusion(all P<0.01); Pranlukast and HAMI 3379 also significantly improved the behavioral function 14 days after reperfusion(P<0.05 or P<0.01). Compared with saline group, the neurological symptom scores in Pranlukast and HAMI 3379 groups presented a trend of amelioration 14 d after reperfusion, but it was not significant(P>0.05). In addition, Pranlukast and HAMI 3379 also inhibited the neuron loss and injury, suppressed microgila and astrocyte activation 14 d after reperfusion(all P<0.01). : CysLTR antagonists Pranlukast and HAMI 3379 have long-term neuroprotective effect on chronic brain injury induced by global cerebral ischemia/reperfusion in gerbils.

UI MeSH Term Description Entries
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D005849 Gerbillinae A subfamily of the Muridae consisting of several genera including Gerbillus, Rhombomys, Tatera, Meriones, and Psammomys. Gerbils,Jird,Meriones,Psammomys,Rats, Sand,Gerbil,Jirds,Merione,Rat, Sand,Sand Rat,Sand Rats
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D018077 Receptors, Leukotriene Cell-surface receptors that bind LEUKOTRIENES with high affinity and trigger intracellular changes influencing the behavior of cells. The leukotriene receptor subtypes have been tentatively named according to their affinities for the endogenous leukotrienes LTB4; LTC4; LTD4; and LTE4. Leukotriene Receptors,Receptors, SRS-A,SRS-A Receptors,Leukotriene Receptor,Receptors, Leukotrienes,SRS-A Receptor,Slow Reacting Substance of Anaphylaxis Receptors,Slow Reaction Substance of Anaphylaxis Receptors,Leukotrienes Receptors,Receptor, Leukotriene,Receptor, SRS-A,Receptors, SRS A,SRS A Receptor,SRS A Receptors
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective
D020024 Leukotriene Antagonists A class of drugs designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level. Leukotriene Antagonist,Leukotriene Receptor Antagonist,Leukotriene Receptor Antagonists,Antagonists, Leukotriene,Receptor Antagonists, Leukotriene,Antagonist, Leukotriene,Antagonist, Leukotriene Receptor,Antagonists, Leukotriene Receptor,Receptor Antagonist, Leukotriene
D020208 Brain Injury, Chronic Conditions characterized by persistent brain damage or dysfunction as sequelae of cranial trauma. This disorder may result from DIFFUSE AXONAL INJURY; INTRACRANIAL HEMORRHAGES; BRAIN EDEMA; and other conditions. Clinical features may include DEMENTIA; focal neurologic deficits; PERSISTENT VEGETATIVE STATE; AKINETIC MUTISM; or COMA. Chronic Brain Injury,Brain Injuries, Chronic,Chronic Brain Injuries

Related Publications

Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
January 2003, The Journal of allergy and clinical immunology,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
October 2003, Sheng li xue bao : [Acta physiologica Sinica],
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
December 1994, Anesthesia and analgesia,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
March 2007, Brain research,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
April 2021, Journal of cardiovascular translational research,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
February 2006, Neurologic clinics,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
April 2010, Chinese journal of integrative medicine,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
May 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
January 2001, Allergy,
Hao Wang, and Honggang Guo, and Qi Lou, and Qiaojuan Shi
September 1996, Molecular and chemical neuropathology,
Copied contents to your clipboard!